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the alleles that underlie the inherited dissimilarities in phenotype
(Rosenstein et al., 2014). However, this hypothesis does not assume
that all of the phenotypic differences are due to germ line genetic alter-
ations, but also epigenetic changes and other factors such as systemic
treatment or tobacco use. Recently, DNA methylation proﬁling of der-
mal ﬁbroblasts obtained from breast cancer patients prior to irradiationExternal beam radiotherapy (EBRT) is the most treatment used in
solid tumors as nearly 50% of cancer patients receive curative EBRT in
theworld. Its success dependsmainly on the total dose homogeneously
delivered within the target volume. Nevertheless, EBRT inevitably ex-
poses surrounding normal tissues andmay cause late and sometimes ir-
reversible toxicities depending on different cells or tissues (stroma,
vascular, parenchymal, immune cells). Interactions between cells or
compartmental tissues and the immune system via cytokines produce
inﬂammatory and pro-ﬁbrotic reactions. Cell depletion, inﬂammation,
repopulation and remodeling are reminiscent of the wound healing
process leading to different severities of late deterministic effects
(Herskind et al., 2016).
Stratifying patients according to the toxicity risk and modulating
EBRT dose would provide a valuable tool for personalized EBRT
(Barnett et al., 2009; Bourgier et al., 2015). Many efforts have been
made to develop assays capable of predicting susceptibility for the de-
velopment of radiation injury that ﬁnally allow customization of EBRT
protocols on an individual basis.
Indeed and as presented in this current volume of EBioMedicine,
Kerns and colleagues (Kerns et al., 2016), aimed to meta-analyze indi-
vidual level data from four genome-wide association studies from pros-
tate cancer radiotherapy cohorts including 1564 men to identify novel
genetic markers of toxicity. A ﬁxed-effects meta-analysis identiﬁed
two SNPs: rs17599026 on 5q31.2 with urinary frequency and
rs7720298 on 5p15.2 with decreased urine stream. These SNPs lie with-
in genes that are expressed in tissues adversely affected by pelvic radio-
therapy including bladder, kidney, rectum and small intestine. The
authors mentioned that new moderate-penetrance genetic variants as-
sociated with radiotherapy toxicity have been identiﬁed. As we know,
radiogenomics (RG) attempts to link germ line genotypic variationsom.2016.07.022.
Oncology, Montpellier Cancer
).
. This is an open access article underand clinical variability observed after EBRT. The aim of RG is to identify
identiﬁed differences associated with ﬁbrosis. One region was charac-
terized as a differentially methylated enhancer of diacylglycerol kinase
alpha (DGKA). Decreased DNA methylation at this enhancer was
shown to enable recruitment of the proﬁbrotic transcription factor
early growth response 1 (EGR1) and then capable to facilitate radia-
tion-induced DGKA transcription in cells from patients later developing
ﬁbrosis. Conversely, inhibition of DGKA showed pronounced effects on
diacylglycerol-mediated lipid homeostasis with proﬁbrotic ﬁbroblast
activation (Weigel et al., 2016).
As mentioned in a recent review by Herskind et al. (2016), pathway
analyses incorporating different ‘omics’ approaches may be more efﬁ-
cient in identifying critical pathways than those based on single
‘omics’ data sets. Integrating these pathways with functional assays
may be powerful in identifying multiple subgroups of EBRT patients
characterized by different mechanisms. In that way, monocentric co-
horts suggested that radiation-induced CD8 T-lymphocyte apoptosis
(RILA) as a functional test can predict late toxicity after curative intent
EBRT. We recently assessed the role of RILA as a predictor of breast ﬁ-
brosis (bf+) after adjuvant breast EBRT in a prospective multicenter
trial (Azria et al., 2015). A total of 502 breast-cancer patients (pts) treat-
ed by conservative surgery and adjuvant EBRT were recruited at ten
centers. RILA was assessed before EBRT by ﬂow cytometry. Impact of
RILA on bf+ (primary endpoint) or relapse was assessed using a com-
peting risk method. With a median follow-up of 38.6 months, grade
≥2 bf+ was observed in 64 pts (14%). A decreased incidence of grade
≥2 bf+ was observed for increasing values of RILA (p = 0.012). No
grade 3 bf+was observed for patientswith RILA ≥12%.Negative predic-
tive value for grade ≥2 bf+ was equal to 91% for RILA ≥20% where the
overall prevalence of grade ≥2 bf+ was estimated at 14%. A signiﬁcant
decrease in the risk of grade ≥2 bf+ was found if patients had no adju-
vant hormonotherapy (sHR = 0.31, p = 0.007) and presented a RILA
≥12% (sHR = 0.45, p = 0.002). Different hypotheses to understand
the mechanisms of inverse correlation between low radiation response
of lymphocytes and the increase risk of developing late reaction after
EBRT are currently under investigations: (i) Production of cytokines
and inﬂammatory immune cells attraction to the irradiated tissuethe CC BY license (http://creativecommons.org/licenses/by/4.0/).
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hanced genomic instability, terminal differentiation of ﬁbroblasts and
increased risk of ﬁbrogenesis (Lacombe et al., 2013); (iii) genetic defect
in the DNA damage response, DNA repair reduction, increased genomic
instability and increased premature terminal differentiation of ﬁbro-
blasts (Herskind et al., 2016).
Clinical implementations with interventional protocols are starting
using this assay permitting distinction between patients without
any over-risk of toxicity (considered as resistant to late effects) and
patients clearly at risk of developing more late effects deﬁned as very
sensitive (Barnett et al., 2015). In terms of altered management,
hyperfractionation can reduce toxicity with no risk of loss of local con-
trol or to allow for dose escalation in very sensitive patients. For more
resistant patients, an increase in dose should be possible and
hypofractionation regimen should be largely proposed leading to a
medicoeconomical improvement of our treatments. This might be in
favor of adding novel targeted or existing systemic therapies (Barnett
et al., 2015).
In conclusion, there is no doubt that personalized radiotherapy driv-
en by companion tests of radiotoxicity but also of tumor radioresponse
will be the standard of care in the near future as it is already the case for
targeted therapies in medical oncology. One size will no longer ﬁt all!
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